Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents, Alkylating / administration & dosage
• Antineoplastic Agents, Alkylating / adverse effects
• Antineoplastic Agents, Alkylating / therapeutic use*
• CD4-Positive T-Lymphocytes / drug effects
• CD8-Positive T-Lymphocytes / drug effects
• Combined Modality Therapy
• Dacarbazine / administration & dosage
• Dacarbazine / adverse effects
• Dacarbazine / therapeutic use*
• Disease Progression
• Disease-Free Survival
• Drug Administration Schedule
• Feasibility Studies
• Female
• Humans
• Immunologic Factors / administration & dosage
• Immunologic Factors / therapeutic use*
• Interferon alpha-2
• Interferon-alpha / administration & dosage
• Interferon-alpha / therapeutic use*
• Killer Cells, Natural / drug effects
• Lymphopenia / chemically induced
• Male
• Melanoma / drug therapy*
• Melanoma / mortality
• Melanoma / pathology
• Middle Aged
• Neoplasm Metastasis
• Recombinant Proteins
• Safety
• Survival Analysis
• Thymalfasin
• Thymosin / administration & dosage
• Thymosin / analogs & derivatives*
• Thymosin / therapeutic use
• Treatment Outcome